Oxaliplatin – Eloxatin® – Elplat® - Debiopharm

Home » Media » Press Releases

Oxaliplatin – Eloxatin® – Elplat®

Date	Article Title
21 Mar 2005	Debiopharm announces import approval from Elplat® (Oxaliplatin) in Japan
07 Feb 2005	Debiopharm S.A. announces marketing approval for a new formulation of Eloxatin® (Oxaliplatin for injection)
03 Jun 2004	Debiopharm´s Eloxatin® (Oxaliplatin) awarded Prix Galien in France for innovative cancer therapy
03 Jun 2004	L´Eloxatine® (Oxaliplatine) de Debiopharm reçoit le Prix Galien en France pour thérapie innovante contre le cancer
04 Mar 2004	Yakult Honsha files Initial Submission for Marketing Authorisation of Debiopharm´s Oxaliplatin in Japan
19 Jan 2004	ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer
11 Jan 2004	Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer
07 Jan 2004	ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in Europe
27 Aug 2002	Debiopharm extends its collaboration with Sanofi-Synthélabo on Eloxatin®
19 Aug 2002	Media Alert: successful registration after shortest ever review by the FDA of Eloxatin

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group